Abou FayadA, RafeiR, NjamkepoE, et al.“An unusual two-strain cholera outbreak in Lebanon, 2022–2023: A genomic epidemiology study”. Nat Commun, 2024; 15(1):6963.
2.
Al KhatibIA, SultanoğluE, SalemM, et al.‘Cholera Response in Northwest Syria; Community perspectives and concerns’. IJEHS, 2024; 5(Continuous):1–11; doi: 10.51757/IJEHS.5.2024.715594p
3.
AliduSO. ‘The theatre and health education: Impact of social media-based short drama in combating COVID-19 vaccine hesitancy in Nigeria’. Ianna Journal of Interdisciplinary Studies, 2021; 3(2):145–151.
4.
ArnaoutAY, NerabaniY, SawasMN, et al.;Aleppo University Hospital Team. ‘Acute watery diarrhea cases during cholera outbreak in Syria: A cohort study’. BMJ Open, 2024; 14(5):e082385.
5.
BeenzuS, EhinmitanE, RunoS, et al.‘The persistent challenge of cholera in Africa: A complex interplay of factors’. RPHB, 2024; 5(4):32–35.
6.
BoseD, BhattacharyaR, KaurT, et al.‘Overcoming water, sanitation, and hygiene challenges in critical regions of the global community’. Water-Energy Nexus [Preprint], 2024; 7:277–296; doi: 10.1016/j.wen.2024.11.003
7.
BriskinE, Bateyi MustafaSH, MahambaR, et al.;Epicentre-MSF DRC cholera working group. ‘Oral cholera vaccine coverage in Goma, Democratic Republic of the Congo, 2022, following 2019–2020 targeted preventative mass campaigns’. Vaccine X, 2024; 20:100555; doi: 10.1016/j.jvacx.2024.100555
8.
CharnleyGEC, KelmanI, GaythorpeKAM, et al.‘Accessing sub-national cholera epidemiological data for Nigeria and the Democratic Republic of Congo during the seventh pandemic’. BMC Infect Dis, 2022; 22(1):288.
9.
D’Mello-GuyettL, CummingO, RogersE, et al.‘Identifying transferable lessons from cholera epidemic responses by Médecins Sans Frontières in Mozambique, Malawi and the Democratic Republic of Congo, 2015–2018: A scoping review’. Confl Health, 2022; 16(1):12.
10.
DashP, HakimA, AkterA, et al.‘Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants’. Msphere, 2024; 9(3):e00565-23.
11.
EnehS, OnukansiF, AnokwuruC, et al.‘Cholera outbreak trends in Nigeria: Policy recommendations and innovative approaches to prevention and treatment’. Front Public Health, 2024; 12:1464361.
12.
GalgaliMS, HelmPJ, ArndtJ. ‘Feeling too isolated to be vaccinated? The contributing role of subjective interpersonal isolation factors towards COVID-19 vaccine hesitancy and resistance’. Soc Sci Med, 2023; 323:115865.
13.
GeorgeCM, ParvinT, BhuyianMSI, et al.‘Randomized Controlled Trial of the Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Cholera Rapid Response Program to Reduce Diarrheal Diseases in Bangladesh’. Int J Environ Res Public Health, 2022; 19(19):12905.
14.
GuanW, et al.‘Transgenic tomato vaccine expressing chimeric protein PAcA/CTB can immunize rats through gastrointestinal absorption’. Chinese Journal of Tissue Engineering Research, 2021; 25(11):1712.
15.
HamorskyKT, KouokamJC, BennettLJ, et al.‘Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks’. PLoS Negl Trop Dis, 2013; 7(3):e2046.
16.
IlboudoPG, et al.‘Cost-effectiveness of a reactive oral cholera immunization campaign using ShancholTM in Malawi’. Cost Effectiveness and Resource Allocation, 2021; 19:1–9.
17.
KimY, ShinB, KimSE, et al.‘A retrospective study on cholera understanding and WASH (water, sanitation, and hygiene) behavior among adolescents in three regions of La Gonâve, Haiti’. J Infect Public Health, 2024; 17(3):443–449.
18.
LebuS, GyimahR, NandoyaE, et al.‘Assessment of sanitation infrastructure resilience to extreme rainfall and flooding: Evidence from an informal settlement in Kenya’. J Environ Manage, 2024; 354:120264; doi: 10.1016/j.jenvman.2024.120264
19.
ManchalN, YoungMK, CastellanosME, et al.‘A systematic review and meta-analysis of ambient temperature and precipitation with infections from five food-borne bacterial pathogens’. Epidemiol Infect, 2024; 152:e98.
20.
MarcusH. (2022) ‘Climate Adaptation in the WASH Sector of East Africa’s Lake Victoria Basin’.
21.
Martinelli FilhoJE, ColwellRR, QueirozAFS, et al.‘Vibrio cholerae O139 attached to zooplankton: Reservoir diversity and distribution over an estuarine-coastal gradient’. Journal of Coastal Research, 2020; 95(sp1):92–96.
22.
MatiasWR, GuillaumeY, Cene AugustinG, et al.‘Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti’. Int J Infect Dis, 2024; 139:153–158.
23.
MiggoM, HarawaG, KangweremaA, et al.‘Fight against cholera outbreak, efforts and challenges in Malawi’. Health Sci Rep, 2023; 6(10):e1594.
24.
MohammedAMA, et al.‘Draft genomes of 10 Vibrio cholerae isolates collected in Sudan in 2019’. Microbiology Resource Announcements, 2024; 13(11):e00376–e24; doi: 10.1128/mra.00376-24
25.
Monreal-EscalanteE, Navarro-TovarG, León-GalloA, et al.‘The corn smut-made cholera oral vaccine is thermostable and induces long-lasting immunity in mouse’. J Biotechnol, 2016; 234:1–6; doi: 10.1016/j.jbiotec.2016.04.047
26.
MukonkaVM, SialubanjeC, MatapoBB, et al.‘Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: A cross-sectional descriptive study’. BMJ Open, 2023; 13(10):e070796.
27.
MulunehMD, NegashK, TsegayeS, et al.‘COVID-19 knowledge, attitudes, and Vaccine Hesitancy in Ethiopia: A Community-based cross-sectional study’. Vaccines (Basel), 2023; 11(4):774.
28.
NasrH, Al-ZumairM, Al-MahbashiT, et al.‘Factors associated with the cholera outbreak in Al-Mahweet-Yemen: Analytic Study’. J Infect Dev Ctries, 2024; 18(1):66–74.
29.
Ng′ OmbeH, et al.‘Immunogenicity and waning immunity from the oral cholera vaccine (ShancholTM) in adults residing in Lukanga Swamps of Zambia’. Plos one, 2022; 17(1):e0262239.
30.
RomateJ, RajkumarE, GreeshmaR. ‘Using the integrative model of behavioural prediction to understand COVID-19 vaccine hesitancy behaviour’. Sci Rep, 2022; 12(1):9344.
31.
SallamM, AthamnehRY, AlkhazalehR, et al.‘Attitude towards cholera vaccination and its related factors in Jordan amid the 2022 Middle East outbreak’. BMC Public Health, 2024; 24(1):2237.
SiamalubeB, EhinmitanE, NgothoM, et al.‘Cholera in Zambia: Explanatory Factors and Mid-term Impact of the Sustainable Development Goals’. Asian J Res Infect Dis, 2024; 15(12):89–105.
34.
SiamalubeB, EhinmitanE, OngusoJ, et al.‘Potential of plant-derived edible vaccines: A vial or a potato? ‘African Journal of Biological Sciences (South Africa), 2024; 6(12):3696–3709.
35.
SiamalubeB. and EmmanuelE E. ‘Cholera-Free Zambia 2025: A Distant Dream or an Achievable Reality? ‘PHOA, 2024; 8(2).
36.
SubediD, PaudelM, PoudelS, et al.‘Food safety in developing countries: Common foodborne and waterborne illnesses, regulations, organizational structure, and challenges of food safety in the context of Nepal’. Food Frontiers [Preprint], 2025; 6(1):86–123.
37.
TatyN, BompangueD, MooreS, et al.‘Spatiotemporal dynamics of cholera hotspots in the Democratic Republic of the Congo from 1973 to 2022’. BMC Infect Dis, 2024; 24(1):360.
38.
TavelliR, CallensM, GrootaertC, et al.‘Foodborne pathogens in the plastisphere: Can microplastics in the food chain threaten microbial food safety? ‘Trends in Food Science & Technology, 2022; 129:1–10.
TrujilloE, AnguloC. ‘Plant‐Made Vaccines Targeting Enteric Pathogens—Safe Alternatives for Vaccination in Developing Countries’. Biotech & Bioengineering, 2025; 122(3):457–480.
41.
TseklevesE, Fonseca BragaM, AbongeC, et al.‘Community engagement in water, sanitation and hygiene in sub-Saharan Africa: Does it WASH? ‘Journal of Water, Sanitation and Hygiene for Development, 2022; 12(2):143–156.
42.
WaltonMG, CubillejoI, NagD, et al.‘Advances in cholera research: From molecular biology to public health initiatives’. Front Microbiol, 2023; 14:1178538.
43.
WheelerJ, RosengartA, JiangZ, et al.‘Informing policy via dynamic models: Cholera in Haiti’. PLoS Comput Biol, 2024; 20(4):e1012032.
44.
World Health Organization International. (2024). Multi-Country Cholera Outbreak. WHO.
45.
XuJ. ‘Harnessing the power of plants: A green factory for bioactive compounds’. Life. MDPI, 2023; 13(10):2041.
46.
YukiY, NojimaM, HosonoO, et al.‘Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: A phase 1 randomized trial’. Lancet Microbe, 2021; 2(9):e429–e440.
47.
YukiY, NojimaM, KashimaK, et al.‘Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults’. Vaccine, 2022; 40(24):3372–3379.
48.
ZeitounA, IbrahimA, Reda El SayedS, et al.‘Descriptive analysis of adverse events following immunization with oral cholera vaccine in Lebanon’. Front Public Health, 2024; 12:1480744.
